Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday

Turnstone Biologics (NASDAQ:TSBX) is expected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Turnstone Biologics to post earnings of ($0.80) per share for the quarter.

Turnstone Biologics Stock Performance

Turnstone Biologics stock opened at $0.35 on Thursday. The company has a 50 day moving average price of $0.43 and a 200-day moving average price of $0.50. Turnstone Biologics has a fifty-two week low of $0.34 and a fifty-two week high of $3.88. The company has a market capitalization of $8.19 million, a PE ratio of -0.11 and a beta of 2.04.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Piper Sandler downgraded shares of Turnstone Biologics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $3.75 to $0.40 in a research note on Wednesday, February 5th. Bank of America downgraded shares of Turnstone Biologics from a “neutral” rating to an “underperform” rating in a research note on Friday, November 15th.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.